Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Hims & Hers Q4 Earnings Preview: What To Expect From Upcoming Report
Hims & Hers Q4 Earnings Preview: What To Expect From Upcoming Report
Nauman Khan
Thu, February 19, 2026 at 9:04 PM GMT+9 1 min read
In this article:
HIMS
-2.64%
NONOF
-1.21%
NVO
-0.28%
This article first appeared on GuruFocus.
Hims & Hers (HIMS) is set to report fourth-quarter fiscal 2025 results after market close on Feb. 23. Analysts expect earnings to decline, while revenue may see a moderate rise.
The telehealth company has faced scrutiny over its copycat weight-loss drugs, a U.S. Food and Drug Administration review, and a patent lawsuit from Novo Nordisk (NYSE:NVO). Investors are watching closely for any updates during the earnings call.
Wall Street forecasts adjusted earnings per share (EPS) of $0.06, down from $0.11 a year earlier. Revenue is projected to reach about $619 million, a 29% increase year-over-year. Hims & Hers has historically beaten estimates in six of the past eight quarters.
Options traders anticipate roughly a 17% swing in HIMS stock following the results, significantly higher than the stock’s average post-earnings movement of about 5% over the last four quarters.
Analysts have revised price targets amid legal and regulatory concerns. Deutsche Bank cut its target to $31, citing delays in a low-cost semaglutide pill launch. Canaccord Genuity lowered its target to $30 after the Novo lawsuit.
Terms and Privacy Policy
Privacy Dashboard
More Info